Lumida
/TMDX
⌘K
Transmedics Group Inc

Transmedics Group Inc

TMDX
$73.98USD-2.66%-2.02 today

MARKET CAP

2.6B

P/E (TTM)

30.7x

FWD P/E

25.1x

DAY RANGE

$73 – $75

52W RANGE

$60
$156

AI Summary

Stalk
Buy NowMedium

Stage 1 is forming an early base after a terminal decline, with a Lockout Rally pattern driving forced upside repricing and confirming institutional demand. Price is holding above rising 9EMA and 21EMA with no exhaustion, creating a bullish asymmetry over the medium term. The Lockout Rally override gives execution permission now, aligning short-term readiness with medium-term bias. Buy now.

  • Q1 revenue $174M, +21% YoY; 2026 guidance $727–757M
  • Europe expansion with PAD Aviation could double market reach
  • Transplant Modernization Act changes create donor volume volatility
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

TransMedics Group, Inc. (NASDAQ: TMDX) is a pioneering company in the field of organ transplantation, specializing in cutting-edge Organ Care System (OCS) technology. Positioned as a leader in the transplant ecosystem, TransMedics aims to enhance organ utilization rates and improve patient outcomes. They are actively expanding their footprint both domestically in the U.S. and through international initiatives, particularly in Europe, to capitalize on a growing global demand for transplantation services amidst supportive regulatory changes.

Bull says

  • Q1 revenue $174M, +21% YoY; 2026 guidance $727–757M
  • Europe expansion with PAD Aviation could double market reach
  • OCS kidney and CHOPS launch drive new revenue opportunities
  • Gross margin ~58% with operating leverage supporting recovery
  • Strong cash balance of $462M funds innovation and growth
  • High profitability and upward analyst revisions bolster outlook

Bear says

  • Transplant Modernization Act changes create donor volume volatility
  • Gross margin declined to ~58%, cost pressures risk further erosion
  • Elevated short interest signals investor skepticism and volatility
  • Intensifying competition in OCS space threatens market share
  • Evercore cut price target to $90 on execution concerns
  • Weak earnings and dividend yields raise return doubts

Investment themes with TMDX

Medical Devices +0.12%

Devices and instruments for medical treatment

ISRG · ABT · SYK

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-09-2026neutral

Transcript signals

Bull points

  • Historically, for the last four or five decades, transplantation has survived and grown when oil prices were high, when oil prices were low, because the market has a mechanism to recover the cost of these when the prices go up.
  • I can assure you, and I assure all the listeners on this call, that Transmedics is doing the absolutely right thing by our customers, and we are having the ability to control our logistics and our fleet, and the network effect that was created here gives us maximum operating leverage on dealing with fuel prices.
  • And to put everybody's mind at ease, fuel charges is a small component of our operating flight hour cost. So, it is covered, and our network is the most cost-efficient way to deal with this problem until it's resolved.

Bear points

  • We are seeing some pressure in the margin in the short term.
  • That's why it's long-term.
  • Our portion of that market is measured in single digits.
Read full transcript analysis ›